GlassScriptPhysician profile
Richard D Funneman
NPI 1396726121
$2,445.84
in general payments reported to CMS, 2019-2025
26 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $286 · 2021: $511 · 2022: $311 · 2023: $385 · 2024: $360 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.33 | 2020-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $304.87 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.19 | 2021-2024 | Xifaxan |
| Mylan Specialty L.P. | $182.14 | 2019-2024 | Yupelri |
| Abbvie INC. | $136.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $107.43 | 2020-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $98.73 | 2020-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $95.47 | 2019-2023 | |
| Pfizer INC. | $86.06 | 2020-2025 | |
| Lundbeck LLC | $78.55 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $58.41 | 2021 | |
| Esperion Therapeutics, INC. | $54.75 | 2021-2025 | Nexletol |
| Allergan, INC. | $51.36 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.70 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.15 | 2024 | Auvelity |
| Almatica Pharma LLC | $23.31 | 2022 | |
| Merck Sharp & Dohme LLC | $19.83 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.27 | 2024 | Rexulti |
| Viatris Specialty LLC | $19.08 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $17.36 | 2022 | |
| Exact Sciences Corporation | $14.77 | 2023 | Cologuard Collection Kit |
| Circassia INC. | $14.10 | 2019 | |
| Amgen INC. | $14.02 | 2022 | |
| Amarin Pharma, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Funneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.